Publisher
Springer Science and Business Media LLC
Reference41 articles.
1. U.S. Food & Drug Administration. NEURONTIN (Gabapentin) Label. Accessed June 7, 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020235s064_020882s047_021129s046lbl.pdf
2. U.S. Food & Drug Administration. GRALISE (Gabapentin) Label. Accessed June 8, 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022544s026lbl.pdf
3. Smith R V., Havens JR, Walsh SL. Gabapentin misuse, abuse and diversion: a systematic review. Addiction. 2016;111(7):1160-1174. https://doi.org/10.1111/add.13324
4. Goodman CW, Brett AS. Gabapentin and Pregabalin for Pain — Is Increased Prescribing a Cause for Concern? N Engl J Med 2017;377(5):411-414. https://doi.org/10.1056/NEJMp1704633
5. Pauly NJ, Delcher C, Slavova S, Lindahl E, Talbert J, Freeman PR. Trends in gabapentin prescribing in a commercially insured U.S. Adult population, 2009-2016. J Manag Care Spec Pharm. 2020;26(3):246-252. https://doi.org/10.18553/jmcp.2020.26.3.246
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献